

REMARKS

With the entry of this Response, Claim 41–81 are pending. Applicants had previously canceled Claims 1–40. In this Response, Applicants have amended Claims 64, 66, 69, 72, 76, 80, and 81 to include a SEQ ID NO. for the claimed peptide or peptide fragment.

Support for the amendments to these claims is found in at least the claims as originally filed. Support for amended Claim 64 is also found in paragraph [0094]. Support for amended Claim 66 is also found in paragraphs [0063], [0065], [0070], [0094], [0095], [0096], and [0242]. Support for amended Claims 69, 72, and 80 is also found in paragraph [0094]. Support for amended Claim 76 is also found in paragraph [0059]. Support for amended Claim 81 is also found in paragraph [0059]. These paragraph numbers refer to the paragraphs in Applicants' published patent application.

Applicants do not believe that these amendments add new matter.

CONCLUSION

With this Response to the Notification of Defective Response, Applicants enclose an amended "Sequence Listing" in TXT form. Applicants believe that this Response is timely filed and that no fee is due; however, Applicants authorize the Commissioner to charge Deposit Account No. 14-0629 any fee that may be required.

Respectfully submitted,

BALLARD SPAHR LLP

/Rebecca C.E. McFadyen, Reg. No. 57,952/

Rebecca C.E. McFadyen, J.D., Ph.D.

Registration No. 57,952

BALLARD SPAHR LLP
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)